Applying causal models to explore the mechanism of action of simvastatin in progressive multiple sclerosis [Neuroscience]
Understanding the mode of action of drugs is a challenge with conventional methods in clinical trials. Here, we aimed to explore whether simvastatin effects on brain atrophy and disability in secondary progressive multiple sclerosis (SPMS) are mediated by reducing cholesterol or are independent of cholesterol. We applied structural equation models...
Source: Proceedings of the National Academy of Sciences - Category: Science Authors: Arman Eshaghi, Rogier A. Kievit, Ferran Prados, Carole H. Sudre, Jennifer Nicholas, M. Jorge Cardoso, Dennis Chan, Richard Nicholas, Sebastien Ourselin, John Greenwood, Alan J. Thompson, Daniel C. Alexander, Frederik Barkhof, Jeremy Chataway, Olga Ciccare Tags: PNAS Plus Source Type: research
More News: Academies | Brain | Cholesterol | Clinical Trials | Disability | Multiple Sclerosis | Neurology | Science | Simvastatin | Statin Therapy | Zocor